摘要
目的:研究黄葵胶囊对难治性肾病综合征(RNS)临床疗效、肾功能、血脂及凝血功能的影响。方法:将赣南医学院第一附属医院2020年8月至2021年8月收治的RNS患者随机分为环孢素(CsA)组(23例)和黄葵胶囊+CsA组(23例)。治疗期间维持环孢素全血谷浓度(100~150)ng/mL,治疗周期6个月。依据肾功能、血脂水平、凝血因子水平及药品不良反应作为评价指标,观察黄葵胶囊+CsA组的临床疗效。结果:与CsA组相比,黄葵胶囊+CsA组经过6个月治疗后完全缓解率、ALB、PT和APTT均显著升高(P<0.05);24h-UTP、TC、FIB和D-D均显著下降(P<0.05);其他指标相比差异无统计学意义(P>0.05)。结论:黄葵胶囊联合CsA,黄葵胶囊通过降低RNS患者蛋白尿和升高血清ALB水平,并改善血脂和凝血相关因子水平,提高患者临床疗效,且不增加患者药品不良反应。
Objective:To study the effect of huangkui capsules on clinical efficacy,renal function,blood lipid and coagulation function of refractory nephrotic syndrome(RNS).Methods:RNS patients were randomly divided into cyclosporine A(CsA)group(23 cases)and huangkui capsules+CsA group(23 cases)in First Affiliated Hospital of Gannan Medical University from August 2020 to August 2021.The treatment cycle was 6 months,and the whole blood trough concentration of cyclosporine(100-150)ng/mL was maintained during the treatment period.According to renal function,blood lipid level,coagulation factor level and adverse drug reactions as evaluation indicators,the clinical efficacy of huangkui capsules+CsA group was observed.Results:Compared with the CsA group,the complete remission rate,ALB,PT and APTT in the huangkui capsules+CsA group were significantly increased after 6 months of treatment(P<0.05).24 h-UTP,TC,FIB and D-D were decreased significantly(P<0.05).Conclusion:Huangkui capsules combined with CsA,huangkui capsules can improve the clinical efficacy of patients by reducing proteinuria and increasing serum ALB levels in patients with RNS,and improving blood lipids and coagulation-related factors,without increasing adverse drug reactions in patients.
作者
倪斌
方春云
高畅
郭春钰
NI Bin;FANG Chunyun;GAO Chang;GUO Chunyu(First Affiliated Hospital of Gannan Medical University,Ganzhou Jiangxi 341000,China)
出处
《药品评价》
CAS
2022年第11期684-688,共5页
Drug Evaluation
基金
江西省中医药管理局科技计划项目(2021A046)
赣州市卫健委科研计划项目(2020-01-21)。
关键词
肾病综合征
黄葵胶囊
环孢素
疗效
Nephritic syndrome
Huangkui capsules
Cyclosporine A
Curative effect
